August 03, 2023
1 min watch
Save
VIDEO: Opthea presents update on sozinibercept for wet AMD
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
SEATTLE — In this Healio Video Perspective from OIS Retina, Megan Baldwin, PhD, provides an update on OPT-302, now called sozinibercept, for the treatment of neovascular age-related macular degeneration.
Sozinibercept is a novel VEGF-C/D “trap” inhibitor designed to provide patients with a greater visual acuity benefit on top of standard-of-care treatment, Baldwin said.
“We are recruiting patients globally, and we are really excited in the short term to be moving the program forward and hope to really demonstrate greater benefits for patients,” she said.
Published by:
Sources/Disclosures
Collapse
Source:
Baldwin M. Innovation showcase. Presented at: OIS Retina; July 27, 2023; Seattle.
Disclosures:
Baldwin reports being CEO and managing director of Opthea Limited.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.